Recent Updates
Recently added Catalysts
DMAC

DiaMedica Therapeutics to Attend 31st Annual ROTH Investor Conference on March 18-19, 2019

Key Takeaway: MINNEAPOLIS, March 12, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that it will be attending the 31st Annual ROTH Conference March 18-19, 2019, at The Ritz Carlton, Laguna Niguel in Dana Point, CA.  DiaMedica’s President and CEO, Rick Pauls

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~16 mo
Low dilution risk
Lead asset
Recombinant human tissue kallikrein
Phase 2 · Acute Ischemic Stroke

Full Press Release Details

MINNEAPOLIS, March 12, 2019 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (Nasdaq: DMAC) today announced that it will be attending the 31st Annual ROTH Conference March 18-19, 2019, at The Ritz Carlton, Laguna Niguel in Dana Point, CA.  DiaMedica’s President and CEO, Rick Pauls, will be hosting one-on-one meetings with institutional investors at the conference and attendees can contact their Roth Capital Partners representative to arrange a meeting.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company focused on developing novel treatments for chronic kidney diseases and neurological disorders. The Company currently has an ongoing phase II study in acute ischemic stroke and a phase Ib study in chronic kidney disease. DiaMedica’s shares are listed on The Nasdaq Capital Market under the trading symbol “DMAC.”
For more information, please visit www.diamedica.com.
Chief Financial Officer
Phone: (763) 496-5118
Vice President of Business Development
Last updated: Mar 12, 2019